ATE205829T1 - Fibrinogen receptor antagonisten mit substituierten b-aminosäurenestern und diese enthaltende pharmazeutische präparate - Google Patents

Fibrinogen receptor antagonisten mit substituierten b-aminosäurenestern und diese enthaltende pharmazeutische präparate

Info

Publication number
ATE205829T1
ATE205829T1 AT95942315T AT95942315T ATE205829T1 AT E205829 T1 ATE205829 T1 AT E205829T1 AT 95942315 T AT95942315 T AT 95942315T AT 95942315 T AT95942315 T AT 95942315T AT E205829 T1 ATE205829 T1 AT E205829T1
Authority
AT
Austria
Prior art keywords
substituted
amino acid
acid esters
receptor antagonists
pharmaceutical preparations
Prior art date
Application number
AT95942315T
Other languages
English (en)
Inventor
Yoshio Hayashi
Takeo Harada
Jun Katada
Akira Tachiki
Takeo Okazaki
Yoshimi Satoh
Hiroshi Miyazaki
Tohru Asari
Original Assignee
Nippon Steel Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Steel Corp filed Critical Nippon Steel Corp
Application granted granted Critical
Publication of ATE205829T1 publication Critical patent/ATE205829T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT95942315T 1994-12-28 1995-12-28 Fibrinogen receptor antagonisten mit substituierten b-aminosäurenestern und diese enthaltende pharmazeutische präparate ATE205829T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP32898094 1994-12-28
JP25284195 1995-09-29
JP34174695A JP3874438B2 (ja) 1994-12-28 1995-12-27 置換β−アミノ酸残基を有するフィブリノーゲン受容体拮抗物質およびそれを有効成分とする医薬製剤
PCT/JP1995/002763 WO1996020172A1 (en) 1994-12-28 1995-12-28 FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED β-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

Publications (1)

Publication Number Publication Date
ATE205829T1 true ATE205829T1 (de) 2001-10-15

Family

ID=27334161

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95942315T ATE205829T1 (de) 1994-12-28 1995-12-28 Fibrinogen receptor antagonisten mit substituierten b-aminosäurenestern und diese enthaltende pharmazeutische präparate

Country Status (10)

Country Link
EP (1) EP0800516B1 (de)
JP (1) JP3874438B2 (de)
KR (1) KR100222391B1 (de)
AT (1) ATE205829T1 (de)
AU (1) AU692656B2 (de)
CA (1) CA2208682C (de)
DE (1) DE69522827T2 (de)
ES (1) ES2164168T3 (de)
TW (1) TW442469B (de)
WO (1) WO1996020172A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3874455B2 (ja) * 1996-06-27 2007-01-31 新日本製鐵株式会社 フィブリノーゲン受容体拮抗物質およびそれを有効成分とする医薬製剤
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
JP5617799B2 (ja) 2010-12-07 2014-11-05 信越化学工業株式会社 化学増幅レジスト材料及びパターン形成方法
KR101975897B1 (ko) 2019-02-12 2019-05-07 주식회사 에스브이티 기밀성이 강화된 볼 밸브
KR20200098358A (ko) 2019-04-16 2020-08-20 주식회사 에스브이티 이중의 씰링부재가 마련되어 기밀성이 강화된 볼 밸브

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2037153A1 (en) * 1990-03-09 1991-09-10 Leo Alig Acetic acid derivatives

Also Published As

Publication number Publication date
DE69522827T2 (de) 2002-04-11
CA2208682C (en) 2002-08-06
ES2164168T3 (es) 2002-02-16
EP0800516A1 (de) 1997-10-15
WO1996020172A1 (en) 1996-07-04
EP0800516B1 (de) 2001-09-19
DE69522827D1 (de) 2001-10-25
TW442469B (en) 2001-06-23
CA2208682A1 (en) 1996-07-04
JP3874438B2 (ja) 2007-01-31
AU692656B2 (en) 1998-06-11
AU4356796A (en) 1996-07-19
JPH09151175A (ja) 1997-06-10
KR100222391B1 (ko) 1999-10-01

Similar Documents

Publication Publication Date Title
SE8804629D0 (sv) New therapeutically active compounds
ATE239726T1 (de) Verschmolzene benzazepinderivate und diese enthaltende pharmazeutische zubereitungen
SE8700499D0 (sv) Novel pharmacologically active compounds
CL2003002756A1 (es) Compuestos derivados de (1-carbamoil-1,1-defenilmetil)-1-[substituido)alquil]purrolidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del sindrome de intestino irritable o incontinencia.
DK320587D0 (da) Nye farmakologiske forbindelser
ES2102475T3 (es) Nuevas alquil-amidas heterociclicas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
EA200200119A1 (ru) β-КАРБОЛИНОВЫЕ ЛЕКАРСТВЕННЫЕ ПРОДУКТЫ
NO894616D0 (no) Fremgangsmaate for fremstilling av anti-aterosklerotisk aktive diarylforbindelser.
NO942952D0 (no) 11-benzaldoksin-17 ater, fremgangsmåte for deres fremstilling samt legemiddel inneholdende slike
SE8804628D0 (sv) New compounds
ATE205829T1 (de) Fibrinogen receptor antagonisten mit substituierten b-aminosäurenestern und diese enthaltende pharmazeutische präparate
ATE38151T1 (de) Bestaendige 5-adenosyl-l-methionin-salze enthaltende, pharmazeutische zusammensetzungen fuer orale anwendung.
LV10267A (lv) Savienojums arstniecibas lidzeklis panemiens savienojuma iegusanai
NO952900L (no) Materiale inneholdende tandospiron eller analoger derav
NO950177D0 (no) Farmakologisk aktive erivater
AU1643592A (en) Novel compound and use of the same as medicine
GEP20002271B (en) Bicyclic Tachykinins Antagonists, Pharmaceutical Composition on Its Basis and Their Use
ATE260672T1 (de) Pharmazeutische lysin enthaltende polypeptid- zusammensetzungen und verfahren zu deren verwendung
DE69011692D1 (de) Therapeutische mittel.
SE8704049D0 (sv) Novel pharmacological compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee